Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +65

Gilead Sciences stock gains fresh support from HIV prevention data

Clinical trial results Drug approval AI-generated analysis

πŸ“ˆ Gilead Sciences reported that 85.6% of participants in the PURPOSE 5 study remained persistent on twice-yearly lenacapavir at Week 52, significantly outperforming the 46.3% persistence rate of daily oral F/TDF.

πŸ›‘οΈ The Phase 2 trial showed zero HIV acquisitions among patients receiving lenacapavir, compared to one acquisition in the F/TDF group where drug levels were low.

πŸ’‰ Gilead's data supports its long-acting HIV prevention strategy by demonstrating that a six-month dosing schedule improves continuity over daily oral regimens.

πŸ“Š The study enrolled patients in the UK and France who needed pre-exposure prophylaxis but were not taking PrEP at enrollment.

πŸ₯ Gilead is presenting additional evidence for Biktarvy and investigational once-weekly or twice-yearly injectable treatments at the HIV Glasgow 2026 congress.

πŸ’° Gilead Sciences stock traded at 151.69 euros on November 10, 2026, following the release of the positive clinical data.

Bullish Signals
  • Gilead Sciences demonstrated superior persistence in its Phase 2 PURPOSE 5 study, with 85.6% of patients remaining adherent to twice-yearly lenacapavir versus 46.3% for daily oral F/TDF at Week 52.
  • The company reported zero HIV acquisitions in the lenacapavir group compared to one in the control group, validating the efficacy of its long-acting injectable prevention strategy.
  • Fresh clinical evidence strengthens Gilead's long-acting HIV portfolio by addressing adherence constraints that limit real-world effectiveness of daily oral regimens.
Full Analysis
Gilead Sciences received fresh positive data from its Phase 2 PURPOSE 5 study, presented ahead of the HIV Glasgow 2026 congress. The trial compared twice-yearly injectable lenacapavir against daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis in patients in the UK and France who were not previously taking PrEP. The study results demonstrated a significant advantage in persistence, with 85.6% of participants on lenacapavir remaining adherent at Week 52 compared to only 46.3% for the daily F/TDF group. Furthermore, no HIV acquisitions occurred in the lenacapavir cohort, whereas one case was observed in the control group, consistent with low drug levels. This data strengthens Gilead's long-acting HIV prevention strategy by addressing adherence constraints that often limit the effectiveness of daily oral regimens. While the findings support the commercial potential of a six-month dosing schedule, investors are now evaluating whether this persistence advantage translates into durable demand and how these new regimens fit within Gilead's broader HIV portfolio. Gilead Sciences stock was trading at 151.69 euros on November 10, 2026. The company is also highlighting other evidence involving Biktarvy and investigational once-weekly or twice-yearly injectable treatments at the congress, though this specific study adds clinical support without establishing future sales figures on its own.